The BUMC Transgenic Core, established in 1995 by Dr. Katya Ravid, has played an important role in the activities of many scientists at our institution. As part of the continual evaluation of all cores, a faculty committee was established to advise Provost Antman and me on the future role of transgenic services at BUMC.
The committee members were unanimously in favor of maintaining a Transgenic Core facility at BU and increasing its capabilities to serve a larger user group. While the committee recognized that implementation of this recommendation will require new investment at a time of fiscal uncertainty, they were convinced that a transgenic core providing state-of-the-art services is essential for maintaining and growing the University’s research portfolio.
After careful consideration of her many leadership commitments, Dr. Ravid has chosen to step down as Scientific Director of the core because of conflicting time commitments. We would like to thank Dr. Ravid for her creative work and efforts on behalf of the institution in establishing and directing the core over the past 20 years. Her insights and efforts contributed to the success of many research projects and grants at BU.
Dr. Kenn Albrecht, a developmental geneticist with broad expertise in the creation and analysis of mouse models of human disease and a collaborator of Dr. Ravid and the Transgenic Core on multiple projects, has agreed to become the new Scientific Director. Please join me in thanking Dr. Ravid for her efforts and Dr. Albrecht for continuing the mission of the Transgenic Core Facility.